Sébastien Barbarot
Prof Sébastien Barbarot is an expert in Dermatology at Centre Hospitalier Universitaire de Nantes (France). As of October 2026, ScienceLeadR ranks Sébastien Barbarot in the top 1% of experts worldwide for Dermatitis, Hypersensitivity and Sexually Transmitted Diseases. Sébastien Barbarot has authored 603 publications, the most recent in 2026, and is an investigator in 48 clinical trials, 12 of them ongoing. SLR score: 2,482 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Immunology - Genetics - Pediatrics
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2005 - 2026
Number : 603
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Peripheral vasomotor symptoms: Expanding the phenotype of GNA11-related capillary malformations. PMID 42755085 — sexually transmitted diseases, capillaries, mosaicism, phenotype, skin diseases, signs and symptoms | J Eur Acad Dermatol Venereol | 2026 | 0 |
| A New Phototherapy Regimen Coupled with Oral Vitamin D Supplementation, for the Long-Term Control of Atopic Dermatitis: A French Multicenter, Randomized, Crossover, Pragmatic Trial. PMID 42728529 — vitamin d, dermatitis, vitamins, phototherapy, genes, tat, therapeutics, dermatitis, atopic | Dermatol Ther (Heidelb) | 2026 | 0 |
| Eczema in inborn errors of immunity with atopy: frequency, timing, phenotypic clustering. PMID 42485622 — syphilis, eczema, phenotype, immunity, cluster analysis, genotype, therapeutics, dermatology, infections, child, autoimmunity | Br J Dermatol | 2026 | 1 |
| Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial. PMID 42473690 — sexually transmitted diseases, quality of life, dermatitis, skin diseases, signs and symptoms, drug-related side effects and adverse reactions, pruritus, therapeutics, pharmaceutical vehicles, dermatitis, atopic | J Eur Acad Dermatol Venereol | 2026 | 0 |
| Can Systemic Treatment for Childhood Psoriasis Be Stopped in Cases of Remission? Data From the ACMe Cohort. PMID 42409581 — skin diseases, cyclosporine, adolescent, therapeutics, psoriasis, acitretin, dermatology, methotrexate, child | Pediatr Dermatol | 2026 | 0 |
Clinical Studies 48
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
12 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Long Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinical trials 2023-506548-18-00 — safety, dermatitis, dermatitis, atopic | Phase 2/Phase 3 | Not yet recruiting | 2022 |
| A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE AA PEDS) 2022-502700-78-00 — safety, alopecia areata, child, alopecia, pharmacokinetics | Phase 3 | Active not recruiting | 2023 |
| Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate to Severe Atopic Dermatitis 2023-508235-31-00 — safety, dermatitis, signs and symptoms, adolescent, therapeutics, dermatitis, atopic | Phase 3 | Active not recruiting | 2024 |
| A Study to Assess the Long Term Safety and Efficacy of Lebrikizumab in Participants 6 Months to 18 Years of Age With Moderate to Severe Atopic Dermatitis (ADorable 2) 2022-501478-21-00 — safety, dermatitis, eczema, dermatitis, atopic | Phase 3 | Recruiting | 2024 |
| Acetylsalicylic Acid Versus Placebo as an add on Treatment to Local Non steroidal Anti inflammatory Drug for the Management of Thrombotic Episodes in Superficial Venous Malformations in Children Aged 6 to 17 Years NCT07663825 — pharmaceutical preparations, venous thrombosis, aspirin, anti-inflammatory agents, non-steroidal, aged, diclofenac, therapeutics, thrombosis, child | Phase 2 | Not yet recruiting | 2026 |
LeadR Networks
Main global connection map